Citius Oncology (NASDAQ:CTOR – Get Free Report) and CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Profitability
This table compares Citius Oncology and CAMP4 Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Citius Oncology | N/A | -99.47% | -42.16% |
| CAMP4 Therapeutics | -2,193.72% | -194.74% | -95.64% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Citius Oncology and CAMP4 Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Citius Oncology | 1 | 0 | 2 | 0 | 2.33 |
| CAMP4 Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Earnings & Valuation
This table compares Citius Oncology and CAMP4 Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Citius Oncology | N/A | N/A | -$24.76 million | ($0.47) | -1.70 |
| CAMP4 Therapeutics | $3.93 million | 53.99 | -$80.40 million | ($2.36) | -1.73 |
Citius Oncology has higher earnings, but lower revenue than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Citius Oncology has a beta of 3.42, suggesting that its share price is 242% more volatile than the S&P 500. Comparatively, CAMP4 Therapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.
Insider & Institutional Ownership
70.5% of Citius Oncology shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Citius Oncology beats CAMP4 Therapeutics on 9 of the 13 factors compared between the two stocks.
About Citius Oncology
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
About CAMP4 Therapeutics
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.
Receive News & Ratings for Citius Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
